NZ237338A - Use of indirect-acting sympathomimetic drugs in the preparation of medicaments for use in enhancing performance - Google Patents
Use of indirect-acting sympathomimetic drugs in the preparation of medicaments for use in enhancing performanceInfo
- Publication number
- NZ237338A NZ237338A NZ237338A NZ23733891A NZ237338A NZ 237338 A NZ237338 A NZ 237338A NZ 237338 A NZ237338 A NZ 237338A NZ 23733891 A NZ23733891 A NZ 23733891A NZ 237338 A NZ237338 A NZ 237338A
- Authority
- NZ
- New Zealand
- Prior art keywords
- indirect
- tyrosine
- performance
- ephedrine
- acting sympathomimetic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 28
- 229940127231 indirect-acting sympathomimetic drug Drugs 0.000 title claims description 12
- 230000002708 enhancing effect Effects 0.000 title claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 29
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 21
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 16
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 16
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 15
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 11
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 229960002179 ephedrine Drugs 0.000 claims description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 6
- 229940025084 amphetamine Drugs 0.000 claims description 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims description 2
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 claims description 2
- 229950002544 aminorex Drugs 0.000 claims description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims description 2
- 229960002837 benzphetamine Drugs 0.000 claims description 2
- 229960003609 cathine Drugs 0.000 claims description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004890 diethylpropion Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229960000436 phendimetrazine Drugs 0.000 claims description 2
- 229960003209 phenmetrazine Drugs 0.000 claims description 2
- 229960003562 phentermine Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
- 229960003908 pseudoephedrine Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 chlophentermine Chemical compound 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000001975 sympathomimetic effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010043087 Tachyphylaxis Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/489,445 US5096712A (en) | 1990-03-06 | 1990-03-06 | Method for enhancing performance so as to improve vigor and decrease fatigue, confusion, tension, and anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ237338A true NZ237338A (en) | 1997-06-24 |
Family
ID=23943891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ237338A NZ237338A (en) | 1990-03-06 | 1991-03-06 | Use of indirect-acting sympathomimetic drugs in the preparation of medicaments for use in enhancing performance |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5096712A (it) |
| JP (1) | JPH04211614A (it) |
| KR (1) | KR910016324A (it) |
| AU (1) | AU636820B2 (it) |
| CA (1) | CA2036750A1 (it) |
| CH (1) | CH683067A5 (it) |
| DE (1) | DE4107180A1 (it) |
| FR (1) | FR2659236B1 (it) |
| GB (1) | GB2241645B (it) |
| IT (1) | IT1249427B (it) |
| NZ (1) | NZ237338A (it) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US5480865A (en) * | 1994-02-25 | 1996-01-02 | Parkinson's Charitable Trust | Nutritional composition |
| US5585101A (en) * | 1995-12-19 | 1996-12-17 | Pacifichealth Laboratories, Inc. | Method to improve performance during exercise using the ciwujia plant |
| US5795880A (en) * | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| AU9197598A (en) * | 1997-08-13 | 1999-03-08 | Nicada, Inc. | Inducing neurotransmitter and neuropeptide activity |
| US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
| US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
| US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
| US20050059743A1 (en) * | 2000-11-01 | 2005-03-17 | Sention, Inc. | Methods for treating mild cognitive impairment and alzheimer's disease |
| US20030232890A1 (en) * | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
| US20070117869A1 (en) * | 2000-11-01 | 2007-05-24 | Cognition Pharmaceuticals Llc | Methods for treating coginitive impairment and improving cognition |
| US7619005B2 (en) * | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| WO2002039998A2 (en) * | 2000-11-01 | 2002-05-23 | Sention, Inc. | Methods and compositions for regulating memory consolidation |
| WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
| WO2010107702A1 (en) * | 2009-03-16 | 2010-09-23 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| ES2626651T3 (es) * | 2011-06-24 | 2017-07-25 | K-Pax Pharmaceuticals, Inc. | Composiciones para el tratamiento de la fatiga crónica |
| US9040082B2 (en) * | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927853A (en) * | 1978-04-24 | 1990-05-22 | Massachusetts Institute Of Technology | Composition for increasing blood pressure |
| US4745130A (en) * | 1978-04-24 | 1988-05-17 | Massachusetts Institute Of Technology | Composition for increasing blood pressure |
| US4327112A (en) * | 1978-04-24 | 1982-04-27 | Massachusetts Institute Of Technology | Process for increasing blood pressure |
| WO1982000250A1 (en) * | 1980-07-15 | 1982-02-04 | R Wurtman | Process for improving vigor and mood in normal human patients |
| ATE30210T1 (de) * | 1981-07-15 | 1987-10-15 | Richard J Wurtman | Zusammensetzung zur erhoehung des blutdrucks. |
| US4673689A (en) * | 1985-09-25 | 1987-06-16 | Massachusetts Institute Of Technology | Method and composition for enhancing the effect of indirect-acting sympathomimetic amines |
| US4598094A (en) * | 1985-09-25 | 1986-07-01 | Massachusetts Institute Of Technology | Method and composition for enhancing the effect of indirect-acting sympathomimetic amines |
| US4885312A (en) * | 1985-09-25 | 1989-12-05 | Massachusetts Institute Of Technology | Method for enhancing the effect of indirect-acting sympathomimetic amines |
| US5019594A (en) * | 1989-11-28 | 1991-05-28 | Interneuron Pharmaceuticals, Inc. | Method for decreasing appetite |
-
1990
- 1990-03-06 US US07/489,445 patent/US5096712A/en not_active Expired - Fee Related
-
1991
- 1991-02-20 CA CA002036750A patent/CA2036750A1/en not_active Abandoned
- 1991-02-28 CH CH613/91A patent/CH683067A5/fr not_active IP Right Cessation
- 1991-03-04 GB GB9104546A patent/GB2241645B/en not_active Expired - Fee Related
- 1991-03-04 FR FR9102541A patent/FR2659236B1/fr not_active Expired - Fee Related
- 1991-03-05 IT ITTO910156A patent/IT1249427B/it active IP Right Grant
- 1991-03-05 JP JP3062445A patent/JPH04211614A/ja active Pending
- 1991-03-05 KR KR1019910003515A patent/KR910016324A/ko not_active Withdrawn
- 1991-03-06 AU AU72665/91A patent/AU636820B2/en not_active Ceased
- 1991-03-06 NZ NZ237338A patent/NZ237338A/en unknown
- 1991-03-06 DE DE4107180A patent/DE4107180A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US5096712A (en) | 1992-03-17 |
| GB9104546D0 (en) | 1991-04-17 |
| CA2036750A1 (en) | 1991-09-07 |
| CH683067A5 (fr) | 1994-01-14 |
| GB2241645B (en) | 1994-10-19 |
| DE4107180A1 (de) | 1991-09-12 |
| IT1249427B (it) | 1995-02-23 |
| FR2659236A1 (fr) | 1991-09-13 |
| AU7266591A (en) | 1991-09-12 |
| ITTO910156A0 (it) | 1991-03-05 |
| JPH04211614A (ja) | 1992-08-03 |
| KR910016324A (ko) | 1991-11-05 |
| FR2659236B1 (fr) | 1995-06-30 |
| GB2241645A (en) | 1991-09-11 |
| AU636820B2 (en) | 1993-05-06 |
| ITTO910156A1 (it) | 1992-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ237338A (en) | Use of indirect-acting sympathomimetic drugs in the preparation of medicaments for use in enhancing performance | |
| US5019594A (en) | Method for decreasing appetite | |
| CA1188617A (en) | Composition for reducing weight | |
| Spasov et al. | Adamantane derivatives: Pharmacological and toxicological properties | |
| Schwarcz et al. | Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues | |
| EP1210118B1 (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
| DE69428523T2 (de) | Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind | |
| Rusy et al. | Gabapentin in phantom limb pain management in children and young adults: report of seven cases | |
| Cucinell et al. | Stimulatory effect of phenobarbital on the metabolism of diphenylhydantoin | |
| US6348498B1 (en) | Control of pain with endogenous cannabinoids | |
| DE69904922T2 (de) | Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält | |
| AU3353199A (en) | Use of cabergoline in the treatment of restless legs syndrome | |
| CA2318095A1 (en) | Methods of treating tardive dyskinesia and other movement disorders | |
| Hull et al. | L-tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. | |
| Stanko | A review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner | |
| Schwarz et al. | Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa | |
| IE84082B1 (en) | Method for treating the premenstrual or late luteal phase syndrome | |
| EP0204954A2 (en) | Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction | |
| ES2293245T3 (es) | Combinacion farmaceutica para el tratamiento de la espasticidad y/o del dolor. | |
| US4293562A (en) | Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine | |
| MXPA02008998A (es) | Tratamiento de trastornos relacionados con el sistema serotonergico. | |
| EP1180058A1 (en) | Combinations of gaba analogs and tricyclic compounds to treat depression | |
| Vardi et al. | The behavioral effect of salbutamol (a beta-adrenergic receptor stimulant) on reserpine-and propranolol-treated rats | |
| Nencini et al. | Tolerance does not develop to the suppressant effects of (−)-norpseudoephedrine on ingestive behavior in the rat | |
| JP2014532752A (ja) | メマンチンとバクロフェンの治療用組み合わせ及びそれらからなる医薬品組成物 |